With a career spanning over 40 years, including 38 years at Abbott/AbbVie, Poulos brings decades of success from a major ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...
Addresses the significant threat of antimicrobial resistance.
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...
Hosted on MSN23h
These Stocks Missed on Earnings, But Will Rebound Next QuarterEarnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback